The Phase 3 TRIUMPH-1 results released in May 2026 told a similar story: the common side effects were nausea, diarrhoea, constipation, vomiting, an altered skin sensation called dysesthesia, and urinary and respiratory infections
But they're basically copying the compounding pharmacies now and selling vials
Yesil S, Sungu N, Kilicarslan A, Kuskonmaz SM, Kara H, Kucuk A, et al
Both candidates are designed to move beyond single-pathway GLP-1 therapy, but they take very different routes: CagriSema combines an amylin analog with semaglutide, while Retatrutide compresses GIP, GLP-1, and glucagon agonism into one investigational peptide
Head to head comparisons show semaglutide produces greater mean HbA1c reduction and weight loss than dulaglutide at clinically relevant doses